NDA 009170 · Valeant
Mysoline
Primidone · Oral · Anti-epileptic Agent
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jun 10, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1954
Mar 8, 1954
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
0 Phase 3, 0 recruiting
FAERS reports
10,264
6,711 serious, 884 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 10, 2026.
INDICATIONS AND USAGE MYSOLINE, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.
Mechanism: ACTIONS MYSOLINE raises electro- or chemoshock seizure thresholds or alters seizure patterns in experimental animals. The mechanism(s) of primidone’s antiepileptic action is not known. Primidone per se has anticonvulsant activity as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). In addition to its anticonvulsant activity, PEMA potentiates the anticonvulsant activity of phenobarbital in experimental animals.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 8, 1954 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- MYSOLINE · PRIMIDONE 50MG · TABLET, ORAL · Prescription · TE AB
- MYSOLINE · PRIMIDONE 250MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Primidone" as an intervention, any sponsor and status, largest first.
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT00068770 · 35 participants · Start Oct 2003 · Primary completion May 2005
Drug: Celecoxib · For: Brain and Central Nervous System Tumors
Sites: Tampa, Florida; Atlanta, Georgia; Baltimore, Maryland · 7 sites in all
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade GliomaCompleted
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT00404248 · 35 participants · Start Jan 2007 · Primary completion Jun 2009
Drug: terameprocol · For: Brain and Central Nervous System Tumors
Sites: Birmingham, Alabama; Tampa, Florida; Atlanta, Georgia · 9 sites in all
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01132040 · 24 participants · Start Aug 2006 · Primary completion Sep 2006
Drug: Primidone · For: Healthy
Sites: HYD, India
Mutual Pharmaceutical Company, Inc.Industry
NCT00685165 · 22 participants · Start May 2004 · Primary completion Jun 2004
Drug: Primidone 50 mg Tablet; Primidone (Mysoline®) 50 mg Tablet · For: Therapeutic Equivalency
- Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel ResistantWithdrawn
Dent Neuroscience Research CenterAcademic, hospital or other
NCT02008123 · 0 participants · Start Aug 2013 · Primary completion Dec 2017
Drug: Primidone · For: Clopidogrel Resistance; Secondary Stroke Prevention
Sites: Amherst, New York
Annick DesjardinsAcademic, hospital or other
NCT00734864 · 0 participants · Start Jun 2009 · Primary completion Jun 2010
Drug: enzyme-inducing anti-epileptic drugs; enzyme-inducing anti-epileptic drugs · For: Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma and 2 more
Sites: Durham, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective845
- fall673
- fatigue650
- tremor591
- off label use509
- dizziness508
- diarrhoea506
- nausea479
- drug interaction410
- headache407
- somnolence392
- dyspnoea368
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 173 |
| 2005 | 195 |
| 2006 | 175 |
| 2007 | 157 |
| 2008 | 184 |
| 2009 | 195 |
| 2010 | 277 |
| 2011 | 300 |
| 2012 | 345 |
| 2013 | 352 |
| 2014 | 391 |
| 2015 | 676 |
| 2016 | 743 |
| 2017 | 666 |
| 2018 | 673 |
| 2019 | 684 |
| 2020 | 692 |
| 2021 | 636 |
| 2022 | 562 |
| 2023 | 591 |
| 2024 | 570 |
| 2025 | 580 |
| 2026 | 446 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mysoline (Primidone)
2024 spending
$12.9M
Beneficiaries
311
2,051 claims
Per beneficiary
$41,489
$53.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,901,520 |
| 2021 | $14,588,744 |
| 2022 | $13,512,438 |
| 2023 | $13,882,536 |
| 2024 | $12,903,028 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Essential tremor.
Ferreira JJ, Sampaio C · BMJ Clin Evid 2007 · Systematic Review
- Topiramate for essential tremor.
Bruno E, Nicoletti A, Quattrocchi G, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Systematic Review
- Pregabalin for essential tremor.
Bruno E, Nicoletti A, Quattrocchi G, et al. · Cochrane Database Syst Rev 2016 · Systematic Review
- Alprazolam for essential tremor.
Bruno E, Nicoletti A, Quattrocchi G, et al. · Cochrane Database Syst Rev 2015 · Systematic Review
- Zonisamide for essential tremor.
Bruno E, Nicoletti A, Filippini G, et al. · Cochrane Database Syst Rev 2017 · Systematic Review
- Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
Dash D, Bruno V, Schwingenschuh P, et al. · Mov Disord 2026 · Systematic Review
Sponsor: Valeant
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.